



April 13, 2017

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) at the 2017 American Academy of Neurology Annual Meeting

- New Phase 3 Data in Lennox-Gastaut Syndrome Selected for Inclusion in the Emerging Science Program -

LONDON, April 13, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the Company will present results from three completed Phase 3 studies of Epidiolex® (cannabidiol or CBD) as adjunctive therapy — two in Lennox-Gastaut syndrome (LGS) and one in Dravet syndrome (DS) — at the American Academy of Neurology (AAN) Annual Meeting, April 22-28, 2017, in Boston. Company-sponsored activities at AAN will be conducted under Greenwich Biosciences, Inc., GW's operating unit in the United States.

"We are very excited to share data from our Phase 3 epilepsy programs with the broader neurology community, particularly new results from the second of our two placebo-controlled studies in Lennox-Gastaut syndrome, which will be featured in the Emerging Science Program during the meeting," said Justin Gover, GW's Chief Executive Officer. "We are looking ahead to finalizing and submitting the NDA to the FDA for Epidiolex in the coming months, which will bring us one step closer towards our goal of making this much-needed treatment available to patients."

Tuesday, April 25, 2017

Clinical Trials Plenary Session

9:15 - 11:30 a.m. (GW Presentation 10:45 - 11:00 a.m.)

Cannabidiol (CBD) reduces convulsive seizure frequency in Dravet syndrome: Results of a multi-center, randomized, controlled trial (GWPCARE1)

Epilepsy/Clinical Neurophysiology (EEG)

1:00 — 3:00 p.m. (GW Presentation 1:00 - 1:12 p.m.)

Presentation 001: Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): Results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4)

Emerging Science Session

5:45 - 7:15 p.m. (GW Presentation 6:06 - 6:09 p.m.)

Poster 008: Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double blind, placebo controlled trial (GWPCARE3)

Wednesday, April 26, 2017

Poster Session 4: Epilepsy/Clinical Neurophysiology (EEG)

11:45 a.m. to 12:35 p.m. (GW Presentation 12:20 - 12:25 p.m.)

Poster 108: A dose ranging safety and pharmacokinetic study of cannabidiol (CBD) in children with Dravet syndrome (GWPCARE1)

Sunday, April 23, 2017

Poster Session 1: Epilepsy and Clinical Neurophysiology: Basic Science

8:30 a.m. to 5:30 p.m. (GW Presentations between 4:00 - 5:30 p.m.)

Poster 224: Cannabidiol does not convert to Δ^9 - tetrahydrocannabinol (THC) in an *in vivo* animal model

Poster 228: The effect of cannabidiol on human CNS-expressed voltage-gated sodium channels

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile

